INmune Bio, Inc. (NASDAQ:INMB) Receives Average Rating of “Reduce” from Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have earned an average rating of “Reduce” from the five research firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $8.00.

Separately, Wall Street Zen lowered INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th.

INmune Bio Trading Down 2.0%

Shares of INmune Bio stock opened at $1.44 on Wednesday. INmune Bio has a 52 week low of $1.38 and a 52 week high of $11.64. The stock has a market cap of $38.28 million, a PE ratio of -0.68 and a beta of 0.72. The company’s 50-day moving average price is $1.68 and its two-hundred day moving average price is $1.87.

Institutional Trading of INmune Bio

Hedge funds have recently bought and sold shares of the company. Royal Bank of Canada boosted its holdings in shares of INmune Bio by 44.8% in the first quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock worth $233,000 after buying an additional 9,236 shares during the period. Jane Street Group LLC purchased a new stake in shares of INmune Bio in the 1st quarter valued at approximately $142,000. Rhumbline Advisers boosted its stake in INmune Bio by 14.4% in the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after purchasing an additional 2,409 shares during the period. Focus Partners Advisor Solutions LLC grew its position in INmune Bio by 321.2% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 48,813 shares of the company’s stock worth $113,000 after purchasing an additional 37,224 shares in the last quarter. Finally, Modera Wealth Management LLC purchased a new position in INmune Bio during the 2nd quarter worth approximately $36,000. 12.72% of the stock is owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.